

Helix BioMedix Strengthens Intellectual Property Position

Four Patents Continue the Expansion of Company's Industry Leading Peptide Portfolio

Bothell, Washington — January 10, 2012 — Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that it has been granted four new U.S. and foreign patents, further strengthening the company's intellectual property assets. The patents focus on dermatological health, where the company continues to build its industry leading intellectual property portfolio. The patents include:

- U.S. patent number 8,071,555 B2, entitled "Protective Skin Care Peptides";
- European patent number 2027152, entitled "Peptide Fragments for Inducing Synthesis of Extra Cellular Matrix Proteins";
- Australian patent number 2006212922, entitled "Antimicrobial Hexapeptides"; and
- Mexican patent number 288451, entitled "Short Bio-Active Peptides for Cellular and Immunological Modulation".

Dr. Lijuan Zhang, Senior Director of R&D Innovation, commented: "Helix BioMedix continues to develop new and innovative technology focused on our core capabilities in dermatology, anti-infectives, cosmeceuticals and personal care. Our ongoing research into the vital functions of the human innate immunity system has led to the identification of a wide array of distinct peptide sequences. Innate immunity peptides act as a first line of defense in the skin and play a key role in the processes controlling infection, modulating inflammation, healing wounds and building tissue."

R. Stephen Beatty, President and CEO stated: "We are pleased to continue our mission of creating value for our shareholders. These patents offer added opportunities for the development of our own products and for use with our peptide distribution partners. We expect to receive additional patent issuances during 2012."

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of structurally diverse bioactive peptides and patents covering hundreds of thousands of peptide sequences. Core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company takes product development programs from theoretical concept to a qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. Striking[®], Cerakine[™], Apothederm[™] and SmartPeptide[™] are trademarks of Helix BioMedix, Inc. More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Forward Looking Statements

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and continue developing marketable peptide-based products, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.